Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma

16 Dec 2022

Abstract excerpt

Standard treatment for patients with high-risk neuroblastoma remains multimodal therapy including chemoradiation, surgical resection, and autologous stem cell rescue. Immunotherapy has demonstrated success in treating many types of cancers; however, its use in pediatric solid tumors has been limited by low tumor mutation burdens. Gastrin-releasing peptide receptor (GRP-R) is overexpressed in numerous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Neuroblastoma Research and Treatments
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36525420
DOI: 10.1371/journal.pone.0277956

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastomaPMID 36525420Read ↗

A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors.Semantic proximity Read ↗

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read ↗

Targeting gastrin-releasing peptide suppresses neuroblastoma progression via upregulation of PTEN signaling.Semantic proximity Read ↗

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myelomaSemantic proximity Read ↗

GD2 targeting CAR T cells for neuroblastomaSemantic proximity Read ↗

Novel Therapies for Relapsed and Refractory NeuroblastomaSemantic proximity Read ↗

GD2-specific Chimeric Antigen Receptor-modified T Cells for the treatment of Refractory and/or Recurrent Neuroblastoma in Pediatric PatientsSemantic proximity Read ↗

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read ↗

Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer.Semantic proximity Read ↗

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHOSemantic proximity Read ↗

G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.Semantic proximity Read ↗

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.